B. Riley Cuts Earnings Estimates for Denali Therapeutics

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts at B. Riley reduced their Q2 2025 earnings per share (EPS) estimates for shares of Denali Therapeutics in a report issued on Wednesday, May 7th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings per share of ($0.86) for the quarter, down from their prior forecast of ($0.80). B. Riley has a "Buy" rating and a $35.00 price target on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. B. Riley also issued estimates for Denali Therapeutics' Q3 2025 earnings at ($0.86) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.43) EPS, FY2026 earnings at ($2.87) EPS, FY2027 earnings at ($1.80) EPS, FY2028 earnings at ($2.52) EPS and FY2029 earnings at $0.27 EPS.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same period last year, the company earned ($0.68) earnings per share.

Several other research analysts have also recently weighed in on DNLI. The Goldman Sachs Group decreased their price target on Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. William Blair upgraded Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. Deutsche Bank Aktiengesellschaft began coverage on Denali Therapeutics in a research note on Tuesday, February 11th. They issued a "buy" rating and a $31.00 price target for the company. Oppenheimer cut their price objective on Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a report on Monday, March 3rd. Finally, Wedbush cut their price objective on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $33.79.

Denali Therapeutics Stock Performance

Shares of DNLI stock traded down $0.19 during mid-day trading on Monday, hitting $13.97. The company's stock had a trading volume of 134,021 shares, compared to its average volume of 1,091,593. Denali Therapeutics has a 52-week low of $10.57 and a 52-week high of $33.33. The business has a 50-day moving average price of $14.13 and a 200 day moving average price of $19.74. The stock has a market cap of $2.03 billion, a price-to-earnings ratio of -5.05 and a beta of 1.49.

Institutional Trading of Denali Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Graham Capital Management L.P. grew its holdings in Denali Therapeutics by 107.7% during the first quarter. Graham Capital Management L.P. now owns 43,005 shares of the company's stock valued at $585,000 after purchasing an additional 22,299 shares during the period. DAFNA Capital Management LLC bought a new stake in Denali Therapeutics during the first quarter valued at about $1,739,000. Tema Etfs LLC purchased a new position in shares of Denali Therapeutics in the first quarter valued at about $206,000. Trexquant Investment LP lifted its position in shares of Denali Therapeutics by 86.7% in the first quarter. Trexquant Investment LP now owns 113,224 shares of the company's stock valued at $1,539,000 after acquiring an additional 52,568 shares in the last quarter. Finally, Walleye Capital LLC lifted its position in shares of Denali Therapeutics by 77.8% in the first quarter. Walleye Capital LLC now owns 44,138 shares of the company's stock valued at $600,000 after acquiring an additional 19,318 shares in the last quarter. Institutional investors own 92.92% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.